BIOPHYTIS (EPA:ALBPS) - Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021

Transparency directive : regulatory news

29/09/2021 08:00

Press release

Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos
(BIO101) in Sarcopenia at the 11th annual International Conference on Frailty
and Sarcopenia Research (ICFSR) September 29 - October 2, 2021

Paris, France, Cambridge (Massachusetts, United States), September 29th, 2021,
08 am CEST
- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage
biotechnology company focused on the development of therapeutics that slow the
degenerative processes associated with aging and improve functional outcomes
for patients suffering from age-related diseases, including severe respiratory
failure in patients suffering from COVID-19, today announces it will present
full results from the SARA-INT Phase 2 trial of Sarconeos (BIO101) in
Sarcopenia at the International Congress on Frailty and Sarcopenia Research
(ICFSR) to be held virtually from September 29 to October 02, 2021.

ICFSR is the key international scientific event on Frailty and Sarcopenia and
is attended by leading researchers, physicians and Biotech/Pharma in this
field.

The results of SARA-INT, with efficacy endpoints including subgroup analysis
and secondary endpoints, will be presented by Cendrine Tourette PhD in a
dedicated seminar on Thursday, September 30 at 9:00-9:30 AM EST. The seminar
will be followed by a Q&A session with Biophytis representatives: Cendrine
Tourette, PhD (SARA Project Leader), Jean Mariani, MD, PhD (Board Director) and
Waly Dioh, PhD (Chief Operating Officer). The Q&A session will be moderated by
Roger A. Fielding, PhD, Principal Investigator of the SARA-INT trial and who
heads the Nutrition, Exercise Physiology & Sarcopenia team at Tufts University
in Boston.

Biophytis has previously announced the top-line results of the SARA-INT study.
Data showed that Sarconeos (BIO101) at the highest dose (350 mg bid)
demonstrated a clinically meaningful improvement in the 400-meter walk test
(400MWT), the primary endpoint of the study. Sarconeos (BIO101) showed a very
good safety profile at the doses of 175 mg bid and of 350 mg bid. Based on the
SARA-INT results, Biophytis is now preparing the phase 3 program and associated
regulatory agency interactions.

About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of therapeutics that are aimed at slowing the degenerative
processes associated with aging and improving functional outcomes for patients
suffering from age-related diseases, including severe respiratory failure in
patients suffering from COVID-19. Sarconeos (BIO101), our leading drug
candidate, is a small molecule, administered orally, being developed as a
treatment for sarcopenia in a Phase 2 clinical trial in the United States and
Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3
study (COVA) for the treatment of severe respiratory manifestations of COVID-19
in Europe, Latin America, and the US. A pediatric formulation of

Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular
Dystrophy (DMD). The Company is based in Paris, France, and Cambridge,
Massachusetts.
The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS
-ISIN: FR0012816825) and ADSs (American Depositary Shares) are listed on Nasdaq
Capital Market (Ticker BPTS -ISIN: US09076G1040). For more information visit
www.biophytis.com

Disclaimer
This press release contains forward-looking statements. Forward-looking
statements include all statements that are not historical facts. In some cases,
you can identify these forward-looking statements by the use of words such as
"outlook," "believes," "expects," "potential," "continues," "may," "will,"
"should," "could," "seeks," "predicts," "intends," "trends," "plans,"
"estimates," "anticipates" or the negative version of these words or other
comparable words. Such forward-looking statements are based on assumptions that
Biophytis considers to be reasonable. However, there can be no assurance that
the statements contained in such forward-looking statements will be verified,
which are subject to various risks and uncertainties. The forward-looking
statements contained in this press release are also subject to risks not yet
known to Biophytis or not currently considered material by Biophytis.
Accordingly, there are or will be important factors that could cause actual
outcomes or results to differ materially from those indicated in these
statements. Please also refer to the "Risk and uncertainties the Company is to
face" section from the Company's 2020 Annual Report available on BIOPHYTIS
website (www.biophytis.com) and as exposed in the "Risk Factors" section of
form 20-F as well as other forms filed with the SEC (Securities and Exchange
Commission, USA). We undertake no obligation to publicly update or review any
forward-looking statement, whether as a result of new information, future
developments or otherwise, except as required by law.

Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com

Media contact
Life Sci Advisors
Sophie Baumont
E: sophie@lifesciadvisors.com
T: +33 6 27 74 74 49

Investor Relations
LifeSci Advisors, LLC
Ligia Vela-Reid
E: lvela-reid@lifesciadvisors.com

BIOPHYTIS's latest news

14/05/2024 07:00

BIOPHYTIS (EPA:ALBPS) - Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories